Viramune European Labeling Warnings Strengthened For Hepatic Reactions
Viramune labeling has been revised in Europe to strengthen warnings following spontaneous postmarketing reports of cutaneous and hepatic reactions.
You may also be interested in...
Revised black box labeling for Boehringer Ingelheim/Roxane antiretroviral Viramune (nevirapine) states that patients must receive liver monitoring during the first 12 weeks of therapy.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011